DelveInsight’s, “Desmoid Tumors Pipeline Insight 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Desmoid Tumors pipeline landscape. It covers the Desmoid Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Desmoid Tumors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Desmoid Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Desmoid Tumors Pipeline Outlook
Key Takeaways from the Desmoid Tumors Pipeline Report
- In May 2025, Nam Bui announced a study of this protocol is treatment. Systemic therapy with oral study agent, nirogacestat, will be given for 3 cycles (1 cycle = 28 days) followed by a single cryoablation procedure between Cycles 3 and 4, and then continued nirogacestat for Cycles 4 through 26. Treatment with nirogacestat may continue via this study for up to 24 months (26 cycles of treatment), unless there is progression of disease, intolerance, subject withdraws their consent, start of a new anticancer therapy, or until Subject Study Completion or Termination occurs.
- DelveInsight’s Desmoid Tumors Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Desmoid Tumors treatment.
- The leading Desmoid Tumors Companies such as Immunome, Iterion Therapeutics and others.
- Promising Desmoid Tumors Pipeline Therapies such as AL102, Nirogacestat, Cryoablation, Sirolimus, Imatinib, FOG-001, mFOLFOX-6, REC-4881 and others.
Stay ahead with the most recent pipeline outlook for Desmoid Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Desmoid Tumors Treatment Drugs
Desmoid Tumors Emerging Drugs Profile
- AL102: Immunome
AL102 is an investigational small molecule gamma secretase inhibitor currently being evaluated for the treatment of desmoid tumors – a debilitating soft tissue malignancy. AL102 is a potential once-daily oral treatment for desmoid tumors. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Desmoid Tumors.
The Desmoid Tumors Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Desmoid Tumors with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Desmoid Tumors Treatment.
- Desmoid Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Desmoid Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Desmoid Tumors market
Explore groundbreaking therapies and clinical trials in the Desmoid Tumors Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Desmoid Tumors Drugs
Desmoid Tumors Companies
Immunome, Iterion Therapeutics and others.
Desmoid Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Desmoid Tumors Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Unveil the future of Desmoid Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Desmoid Tumors Market Drivers and Barriers
Scope of the Desmoid Tumors Pipeline Report
- Coverage- Global
- Desmoid Tumors Companies- Immunome, Iterion Therapeutics and others.
- Promising Desmoid Tumors Pipeline Therapies- AL102, Nirogacestat, Cryoablation, Sirolimus, Imatinib, FOG-001, mFOLFOX-6, REC-4881 and others.
- Desmoid Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Desmoid Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Desmoid Tumors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Desmoid Tumors Companies, Key Products and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- Desmoid Tumors: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Desmoid Tumors – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- AL102: Immunome
- Mid-Stage Products (Phase II/III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Desmoid Tumors Key Companies
- Desmoid Tumors Key Products
- Desmoid Tumors- Unmet Needs
- Desmoid Tumors- Market Drivers and Barriers
- Desmoid Tumors- Future Perspectives and Conclusion
- Desmoid Tumors Analyst Views
- Desmoid Tumors Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/desmoid-tumors-pipeline-insight